Alcon shares surge 5.14% after-hours on strong Q3 results, driven by equipment growth and Unity VCS momentum.

Alcon (ALC) surged 5.14% in after-hours trading following the release of its Q3 2025 results, which highlighted 6% reported sales growth to $2.6 billion, driven by strong acceleration in equipment and ocular health segments. The company emphasized momentum in Unity VCS surgical platforms and early success with PanOptix Pro and Tryptyr, positioning it for 2026 growth. Core diluted EPS of $0.79 and reaffirmed full-year guidance ($10.3–$10.4 billion sales) further reinforced investor confidence. Despite a slight revenue miss in one report, the overall positive earnings report, robust orderbook, and strategic product traction aligned with the stock’s upward move.